US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neumora Therapeutics, Inc.

0.7798

+0.01281.67%

Post-market: 0.7700-0.0098-1.26%19:21 EDT

Volume:804.65K

Turnover:613.83K

Market Cap:126.13M

PE:-0.51

High:0.7798

Open:0.7630

Low:0.7315

Close:0.7670

Loading ...

Overview Company News Filings

Neumora trial failure a ‘big blow’ to bull case, says Stifel

Sector Update: Health Care Stocks Edge Higher Premarket Thursday

MT Newswires Live

Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint

Wall Street Kicks Off 2025 in Upbeat Mood, Lifting US Equity Futures

MT Newswires Live

Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials

Neumora Therapeutics: Untapped Potential Amidst Ongoing Trials and Anticipated Positive Developments

Neumora Plunges After Depression Drug Fails in Final-Stage Study

BUZZ-Neumora falls over 80% as depression drug fails in late-stage study

Neumora Shares Down 79% Premarket After Co's Depression Drug Fails to Meet Main Goal in a Late-Stage Trial

THOMSON REUTERS

Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression

Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints

Neumora Therapeutics' depression drug fails to meet main goal of late-stage study

Neumora Therapeutics Inc - Navacaprant Well-Tolerated With Safety Profile Comparable to Placebo

THOMSON REUTERS

Neumora Therapeutics Inc - Study Shows No Significant Improvement in Depressive Symptoms

THOMSON REUTERS

Neumora Therapeutics Inc - Navacaprant Showed Efficacy Signal in Female Participants

THOMSON REUTERS

Neumora Therapeutics Reports Data From Koastal-1 Study of Navacaprant in Major Depressive Disorder

THOMSON REUTERS

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Neumora Therapeutics Inc put volume heavy and directionally bearish

Neumora Therapeutics Inc put volume heavy and directionally bearish

Neumora Therapeutics Inc put volume heavy and directionally bearish

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NMRA/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":0.7798,"timestamp":1746043200000,"preClose":0.767,"halted":0,"volume":804653,"hourTrading":{"tag":"盘后","latestPrice":0.77,"preClose":0.7798,"latestTime":"19:21 EDT","volume":2615,"amount":2034.6734,"timestamp":1746055289688},"delay":0,"floatShares":53514397,"shares":161747922,"eps":-1.529624,"marketStatus":"Closed","change":0.0128,"latestTime":"04-30 16:00:00 EDT","open":0.763,"high":0.7798,"low":0.7315,"amount":613825.8396462,"amplitude":0.062973,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.529624,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746086400000},"marketStatusCode":5,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.767,"preHourTrading":{"tag":"盘前","latestPrice":0.7849,"preClose":0.767,"latestTime":"08:08 EDT","volume":3,"amount":2.3697,"timestamp":1746014886423},"postHourTrading":{"tag":"盘后","latestPrice":0.77,"preClose":0.7798,"latestTime":"19:21 EDT","volume":2615,"amount":2034.6734,"timestamp":1746055289688},"volumeRatio":0.803036,"impliedVol":0.8389,"impliedVolPercentile":0.344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":53514397,"roa":"-40.50%","roe":"-64.48%","lyrEps":-1.529624,"volumeRatio":0.803036,"shares":161747922,"dividePrice":0,"high":0.7798,"amplitude":0.062973,"preClose":0.767,"low":0.7315,"week52Low":0.6211,"pbRate":"0.44","week52High":17.1874,"institutionHeld":0,"latestPrice":0.7798,"eps":-1.529624,"divideRate":0,"volume":804653,"delay":0,"ttmEps":-1.529624,"open":0.763,"prevYearClose":10.6,"prevWeekClose":0.7575,"prevMonthClose":1,"prevQuarterClose":1,"fiveDayClose":0.7109,"twentyDayClose":0.9133,"sixtyDayClose":1.86,"earningDate":1746979200000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500922543","title":"Neumora trial failure a ‘big blow’ to bull case, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2500922543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500922543?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:20","pubTimestamp":1735827613,"startTime":"0","endTime":"0","summary":"After Neumora Therapeutics (NMRA) announced the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder did not demon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-trial-failure-a-big-blow-to-bull-case-says-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-trial-failure-a-big-blow-to-bull-case-says-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4007","BK4127","NMRA"],"gpt_icon":0},{"id":"2500000921","title":"Sector Update: Health Care Stocks Edge Higher Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2500000921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500000921?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:12","pubTimestamp":1735827162,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Thursday, with the iShares Biotechnology ETF  and The Health Care Select Sector SPDR Fund  up 0.6%.Neumora Therapeutics  shares were down more than 82% after the company said that the phase 3 KOASTAL-1 study of navacaprant in treating major depressive disorder failed to meet its primary endpoint.Hutchmed   shares were up more than 5% after the company said overnight that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.ANI Pharmaceuticals  shares were up over 4% after the company said it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","NMRA","HCM","IBB","BK4007","BK4581","BK4531","XLV","ANIP","BK4588"],"gpt_icon":0},{"id":"2500392454","title":"Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2500392454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500392454?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:00","pubTimestamp":1735826437,"startTime":"0","endTime":"0","summary":"Check out this morning’s top movers from around Wall Street, compiled by The Fly.  HIGHER – Topgolf Callaway (MODG) up 8% after Jefferies upgr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/morning-movers-neumora-therapeutics-plummets-after-koastal-1-misses-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/morning-movers-neumora-therapeutics-plummets-after-koastal-1-misses-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4139","BK4007","MODG","LENZ","BK4190"],"gpt_icon":0},{"id":"2500929292","title":"Wall Street Kicks Off 2025 in Upbeat Mood, Lifting US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2500929292","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500929292?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:53","pubTimestamp":1735825987,"startTime":"0","endTime":"0","summary":"US equity futures rose ahead of Thursday's opening bell to begin 2025 in an upbeat mood as traders digested jobless claims data.Dow Jones Industrial Average futures rose 0.7%, S&P 500 futures increase","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SDOW","USAW.SI","EQR","BK4116","NET","UDOW","BK7016",".DJI","NET.AU","USJW.SI","BK4588","NMRA","TSYW.SI","BK4215","MNQmain","BK4548","BK4554","BK4585",".SPX",".IXIC","DJX","NQmain","BK4560","LU2286300806.USD","NVIW.SI","DDM","PSQ","DOG","QID","QLD","TQQQ","BK4007","SQQQ","DXD"],"gpt_icon":1},{"id":"2500929163","title":"Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2500929163","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500929163?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:30","pubTimestamp":1735824628,"startTime":"0","endTime":"0","summary":"On Thursday,Neumora Therapeutics, Inc. stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder.The KOASTAL-1 Study is the first of three replicate Phase 3 studies that comprise the pivotal KOASTAL program.The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale  total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale  scale.Also Read: Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?“We are disappointed by the results from KOASTAL-1 as they were not consistent with the body of evidence supporting this mechanism in MDD. There is a lot to investigate from this study, in particular the contrast in drug and placebo responses in depressed mood and anhedonia in female participants compared to male participants,” said Rob Lenz,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-therapeutics-depression-drug-fails-133028449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","NMRA","BK4007"],"gpt_icon":0},{"id":"2500926707","title":"Neumora Therapeutics: Untapped Potential Amidst Ongoing Trials and Anticipated Positive Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2500926707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500926707?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:25","pubTimestamp":1735824313,"startTime":"0","endTime":"0","summary":"Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) today and set a price target of $23.00. Am...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-untapped-potential-amidst-ongoing-trials-and-anticipated-positive-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-untapped-potential-amidst-ongoing-trials-and-anticipated-positive-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","NMRA"],"gpt_icon":0},{"id":"2500165929","title":"Neumora Plunges After Depression Drug Fails in Final-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2500165929","media":"Bloomberg","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500165929?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:06","pubTimestamp":1735823218,"startTime":"0","endTime":"0","summary":" -- Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage study for treatment of major depressive disorder.Patients who received Neumora’s navacaprant didn’t show a statistically significant improvement in a measurement of depression symptoms, the company said Thursday. The shares fell as much as 82% in trading before US markets opened.Some analysts had hailed navacaprant as a promising new way to treat major depressive disorder, which affects some 21 million people annually in the US. Guggenheim analyst Yatin Suneja had said Neumora shares could double or triple if studies were successful.Neumora is running two more final-stage trials of the drug, and is developing a number of other drugs for brain disorders.The company’s cash balance of over $340 million as of the end of the third quarter “provides runway into mid-2026,” Henry Gosebruch, Neumora’s chief executive officer, said in the statement. Its market capitali","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-plunges-depression-drug-fails-130658715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NMRA","SSI","BK4007"],"gpt_icon":0},{"id":"2500238399","title":"BUZZ-Neumora falls over 80% as depression drug fails in late-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2500238399","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500238399?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:39","pubTimestamp":1735821550,"startTime":"0","endTime":"0","summary":"** Drug developer Neumora Therapeutics'    shares fall 82% to $1.95   ** NMRA says its experimental depression drug, navacaprant, did not meet the main goal in a late-stage trial   ** The drug did not reduce symptoms of depression as measured on a disease severity scale that tracks sadness, reduced sleep and pessimistic thoughts   ** NMRA says the drug also did not show statistically significant improvement on a key secondary goal    ** Co says its cash balance of $342 mln at the end of the Q3 will fund operations into mid-2026   ** NMRA declined ~38% in 2024 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-Neumora falls over 80% as depression drug fails in late-stage study","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":1},{"id":"2500928192","title":"Neumora Shares Down 79% Premarket After Co's Depression Drug Fails to Meet Main Goal in a Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2500928192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500928192?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:31","pubTimestamp":1735821103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nFWN3NY0P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500108928","title":"Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2500108928","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500108928?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:20","pubTimestamp":1735820426,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-navacaprant-did-not-meet-primary-endpoint-in-depression?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-navacaprant-did-not-meet-primary-endpoint-in-depression?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","NMRA","LENZ"],"gpt_icon":0},{"id":"2500940041","title":"Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940041","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940041?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:17","pubTimestamp":1735820220,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement.Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60.The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale.\"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch.Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","NMRA","BK4007"],"gpt_icon":0},{"id":"2500940693","title":"Neumora Therapeutics' depression drug fails to meet main goal of late-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940693","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940693?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:06","pubTimestamp":1735819578,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics' depression drug fails to meet main goal of late-stage studyJan 2  - Neumora Therapeutics NMRA.O said on Thursday its experimental  drug to treat depression failed to meet the main goal of a late-stage study.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4N3NY0HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500940854","title":"Neumora Therapeutics Inc - Navacaprant Well-Tolerated With Safety Profile Comparable to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940854?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:00","pubTimestamp":1735819201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA4PH7GC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500940832","title":"Neumora Therapeutics Inc - Study Shows No Significant Improvement in Depressive Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940832?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:00","pubTimestamp":1735819201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA4PH7GC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500894083","title":"Neumora Therapeutics Inc - Navacaprant Showed Efficacy Signal in Female Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2500894083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500894083?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:00","pubTimestamp":1735819201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA4PH7GC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500694089","title":"Neumora Therapeutics Reports Data From Koastal-1 Study of Navacaprant in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2500694089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500694089?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:00","pubTimestamp":1735819201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA4PH7GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500940525","title":"Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940525","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940525?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:00","pubTimestamp":1735819200,"startTime":"0","endTime":"0","summary":"Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an effic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/02/3003449/0/en/Neumora-Therapeutics-Reports-Data-from-KOASTAL-1-Study-of-Navacaprant-in-Major-Depressive-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4007","BK4017","LENZ","NMRA","KOR","BK4139"],"gpt_icon":0},{"id":"2494638457","title":"Neumora Therapeutics Inc put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2494638457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494638457?lang=en_us&edition=fundamental","pubTime":"2024-12-27 23:35","pubTimestamp":1735313706,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Neumora Therapeutics (NMRA) Inc with 6,521 puts trading, or 9x expected. Most active are Jan-25 5 puts and Jan-25 7.5 puts, w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-put-volume-heavy-and-directionally-bearish-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-put-volume-heavy-and-directionally-bearish-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2493033610","title":"Neumora Therapeutics Inc put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2493033610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493033610?lang=en_us&edition=fundamental","pubTime":"2024-12-24 23:35","pubTimestamp":1735054506,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Neumora Therapeutics (NMRA) Inc with 6,162 puts trading, or 10x expected. Most active are Jan-25 5 puts and Jan-25 2.5 puts, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-put-volume-heavy-and-directionally-bearish-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-put-volume-heavy-and-directionally-bearish-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2493476075","title":"Neumora Therapeutics Inc put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2493476075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493476075?lang=en_us&edition=fundamental","pubTime":"2024-12-21 04:35","pubTimestamp":1734726917,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Neumora Therapeutics (NMRA) Inc with 8,496 puts trading, or 8x expected. Most active are Jan-25 5 puts and Jan-25 15 calls, w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-put-volume-heavy-and-directionally-bearish?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-put-volume-heavy-and-directionally-bearish?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NMRA","LENZ","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":115,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"NMRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"defaultRemindTime":1747080000000,"name":null,"time":"Post Market","dateTimestamp":1747022400000,"actualEps":null},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.5556,"sell":0.1111,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.5556,"analysts":9,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2025-04-29","current":-0.50597,"percent":0.960317,"low":-19.620035,"twenty":-12.279982,"median":-6.898905,"eighty":-1.320222,"high":-0.41859,"avg":-7.884911,"sd":5.021329,"marketCap":123348965},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-04-29","current":-0.50597,"twenty":-12.279982,"median":-6.898905,"eighty":-1.320222,"marketCap":123348965}],"updateTime":1746019581319}}}